Expert Interview
Reviewing the Valeda System from Lumithera, a light-based therapy for geographic atrophy
Ticker(s): LUMITHERA, APLS, ALPMFInstitution: Rush University & Illinois Retina Associates
- Assistant Professor of Ophthalmology at Rush University Medical Center & co-investigator on several clinical trials.
- Manages 20 patints a week with wAMD.
- Research interests include assessing the color performance of the NGENUITY 3D visualization system and meta-analyses of cytokines in various retinal diseases; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula.
Roughly how many patients do you manage for geographic atrophy?
Added By: ben_adminCan you discuss the current standard of care for GA?
Added By: ben_adminWhat are your thoughts on the potential of the Valeda system?
Added By: ben_adminHow many geographic atrophy (GA) patients do you manage monthly, and have referrals increased with new GA medication approvals like Syfovre or Izervay?
Added By: slingshot_insightsWho are the ideal patients for Syfovre, Izervay, and the new Valeda Light Delivery System, and how does Valeda compare to current GA medications in terms of efficacy and safety?
Added By: slingshot_insightsAre there upcoming GA clinical trials or therapies you're particularly interested in, and how might these influence treatment protocols or market adoption?
Added By: slingshot_insightsCould you discuss the logistics, such as treatment frequency, reimbursement, patient burden, and whether Valeda could be used in non-specialist settings like optometry offices?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
